EP0598037A1 - Formulation tamponnee de peg-sod - Google Patents

Formulation tamponnee de peg-sod

Info

Publication number
EP0598037A1
EP0598037A1 EP92917825A EP92917825A EP0598037A1 EP 0598037 A1 EP0598037 A1 EP 0598037A1 EP 92917825 A EP92917825 A EP 92917825A EP 92917825 A EP92917825 A EP 92917825A EP 0598037 A1 EP0598037 A1 EP 0598037A1
Authority
EP
European Patent Office
Prior art keywords
peg
sod
buffer
msod
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92917825A
Other languages
German (de)
English (en)
Inventor
George C. Na
Natarajan Rajagopalan
Barbara O-Ching Yuan
Kim Marie Revello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Sterling Winthrop Inc filed Critical Sanofi SA
Publication of EP0598037A1 publication Critical patent/EP0598037A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to an aqueous formulation for a conjugate of mammalian superoxide dismutase with polyethy- lene glycol (PEG-SOD) comprising PEG-SOD and non-chelating buffer in the range from pH 5.0 to pH 6.5.
  • PEG-SOD polyethy- lene glycol
  • the invention further relates to a method of using the formulation for the prevention and treatment of oxidant injury in a mammal.
  • Ha aguchi et al. European Application 225,130 discloses an aqueous solution of 0.067 M phosphate-buffered saline (pH 7.2, 287 mOsm) containing 25 g of manganese SOD conjugated to polyethylene glycol of molecular weight 5,000 in 5 mL of distilled water.
  • Hamaguchi states “In this manner a ... liposome composition having SOD-PEG (5000) entrapped in stable condition was obtained. " This is the only reference of which the inventors are aware that discloses the stability of any solution of a superoxide dismutase that is conjugated to a polyethylene glycol.
  • the SOD is not a mammalian Cu/Zn-SOD, but rather is a Mn-SOD from a microorganism.
  • the PEG is directly attached to the SOD by an amide bond, as contrasted with the PEG-SOD of the invention in which the PEG and the SOD are linked through succinyl amide/ester bonds.
  • PEG-S-mSOD A conjugate of a mammalian SOD and polyethylene glycol or a lower-alkoxypolyethylene glycol connected by a succinyl residue having an ester linkage to the PEG and an amide linkage to an amino function in the SOD will hereinafter be referred to as PEG-S-mSOD.
  • the term polyethylene glycol or PEG when used herein refers to the compound or mixture of compounds of formula R-0-(CH 2 CH 2 ⁇ ) n OH wherein R is hydrogen or alkyl of one to four carbons and n is an integer from 80 to 25,000.
  • PEG-S-mSOD solutions which we obtained from Enzon (South Plainfield, NJ, USA) , were formulated by Enzon at pH 7.3 in phosphate buffer.
  • Enzon slightly acidic
  • aqueous formulations of PEG-S-mSOD arises from the particular utility of PEG-S-mSOD for the treatment and prevention of oxidative injury in a clinical setting.
  • parenteral administration is preferred.
  • a clinically useful parenteral formulation must have a reasonable shelf life under convenient storage conditions or the parenteral solution must be freshly prepared shortly before each use. Obviously, the former is much preferred.
  • Our invention provides an aqueous solution, suitable for parenteral administration that, for the first time, allows storage under convenient conditions for economically practical lengths of time.
  • the invention in a composition of matter aspect relates to an aqueous formulation of PEG-S-mSOD comprising PEG-S-mSOD and a non-chelating buffer in the range from pH 5.0 to 6.5, preferably from pH 5.8 to pH 6.2.
  • Fig. 1 shows the stability of PEG-S-mSOD (1) as the percent of initial enzymic activity as a function of pH
  • Fig. 2 shows the rate of production of free PEG and methoxy PEG in mg/mL (degradation) as a function of time in days for a solution of the invention at pH 6.2 and a solu ⁇ tion of the prior art at pH 7.3.
  • Superoxide dismutase is the name given to a class of enzymes that catalyze the breakdown of the superoxide anion radical (0 2 ⁇ -) to oxygen and hydrogen peroxide.
  • SOD is known under the systematic nomenclature of the International Union of Biochemistry as superoxide oxidore- ductase and has a classification number of 1.15.1.1. Such substances have been called orgoteins and hemocupreins as well as superoxide dismutases and range in molecular weight from about 400 to about 48,000.
  • the copper-zinc dismutases are a remarkably conserved family with respect to gross structural properties. Without exception, the purified. enzymes have been shown to be di ers (molecular weight usually 31,000-33,000) containing two moles each of copper and zinc ions per mole.
  • the enzymes of the manganese/iron family are not as uniform in such basic properties as molecular weight, subunit structure and ⁇ metal content.
  • mSOD mammalian Zn/Cu superoxide dismutases
  • mSOD may be of any origin. It is commercially obtained from bovine erythro- cytes and huma'n erythrocytes as well as by recombinant synthesis in microorganisms such as E. coli and yeast. Human and bovine SOD are preferred.
  • mSOD is covalently linked to polymers to provide conjugates that retain enzymic activity. Such conjugates display greatly extended half-lives in the blood stream.
  • Preferred conjugates comprise recombinant or native human SOD or bovine SOD covalently linked to polyethylene glycol (PEG) through a succinyl residue as described in US Patent 4,179,337, which is incorporated herein by reference.
  • the preferred polyethylene glycol has a formula of R-O-(CH 2 -CH 2 ⁇ ) n OH wherein R is hydrogen or methyl and n is about 112.
  • the preferred PEG is of molecular weight from 1 x 10 3 to 2 x 10 5 , preferably 1 x 10 3 to 2 x 10 4 , and the conjugate is modified from about 25 to about 99 percent in terms of the available lysine residues, preferably about 45 to about 70 percent. It is preferred that the PEG-S-mSOD have a specific activity greater than about 1000 U/mg of mSOD as determined by the method of Fridovich and McCord [J. Biol. Chem. 244. 6049-6055 (1969)].
  • the buffers that comprise the other critical component of the formulations of the invention include pharmaceuti ⁇ cally acceptable, non-chelating buffers that maintain the pH at 5.0 to 6.5.
  • pharmaceutically acceptable is meant buffers that are relatively innocuous to the animal organism in medicinal doses of the buffers so that the beneficial properties inherent in the PEG-S-mSOD are not vitiated by side effects ascribable to the buffers.
  • other appropriate medicinally acceptable buffers within the scope of the invention include those derived from other mineral acids and organic acids, preferably dicarboxylic organic acids. Phosphate and adipate buffers are
  • SUBSTITUTE SHEET particularly preferred.
  • non-chelating it is meant that the buffer does not contain a component, usually the anionic component, that chelates or sequesters either copper or zinc ions in aqueous solutions.
  • the buffers may be present in any concentration that is high enough to maintain the pH at a set level but low enough so as not to introduce adverse pharmacological effects from the buffer itself.
  • the minimum concentration of buffer necessary to maintain a set pH is a function of the amount and form of the PEG-S-mSOD in the solution and the relation of the pK a of the conjugate acid in the buffer to the desired pH of the solution. More buffer will be required at minimum to establish and maintain the desired pH when the pH is farther from the pK a of the buffer or when the concentration of PEG-S-mSOD is higher.
  • Concentrations of PEG-S-mSOD may range from 100 U to 150,000 U/mL.
  • the minimum buffer concentration is about 30 mM for phosphate buffer at pH 6.2.
  • Other operable solutions of the invention may have buffer concentrations ranging from about 10 mM to about 500 mM, preferably 30 mM to 50 mM.
  • a formula ⁇ tion of the invention may contain, in addition to PEG-S- mSOD and a buffer, isotonic agents, preferably 140 to 150 mM sodium chloride, and, optionally, preservatives.
  • the mSOD used in the experiments was SOD from bovine liver, purchased from DDI Pharmaceuticals (Mountain View, CA) .
  • PEG-S-mSOD was purchased from Enzon Inc. (South Plainfield, NJ) and was equivalent to 3000 ⁇ 600 u/mg.
  • Example 1 Representative compositions of the invention have been prepared as follows: Example 1
  • Isotonic Phosphate Buffer pH 6.2 A solution of 5.071 g of USP/NF, monobasic sodium phos ⁇ phate monohydrate, 3.552 g of USP/NF dibasic sodium phosphate heptahydrate and 8.500 g of USP/NF sodium chloride in 800 mL of USP/NF water for injection was prepared and brought to 1.000 L with water for injection. The pH was checked and if found to fall outside the range of 6.1 to 6.3, the solution was discarded.
  • Isotonic Phosphate Buffer pH 6.0 A solution of 5.623 g of monobasic sodium phosphate monohydrate, 2.48 g of dibasic sodium phosphate heptahy ⁇ drate, and 8.500 g of sodium chloride in 800 mL of water for injection was prepared and brought to 1.000 L with water for injection. The pH was checked and if found to fall outside the range of 5.9 to 6.1, the solution was discarded.
  • PEG-S-mSOD was dialyzed against the buffer of interest for 24 hours at 4°C.
  • the protein concentration was approximately 3.3 mg/mL.
  • the solutions were filtered through 4 mm sterile Millex-GV 0.22 ⁇ m filters and added directly to glass vials under sterile conditions.
  • Kimble 2 mL or 5 mL USP' type I glass vials, West 4416/50 gray Teflon-coated butyl stoppers, and West FO Lacq crimp tops were used.
  • the fill volume was usually 1-3 mL.
  • the samples were stored in the dark at constant temperature. The stability of each sample was determined by monitoring its enzyme activity, the amount of free PEG, and its solution clarity. The pH of the solution was also checked to ensure sufficient buffer capacity.
  • a TSK 2000 PWXL column and a TSK 3000 PWXL column were connected in a series.
  • the mobile phase consisted of 0.1 M NaCl, 0.1 M NaPi buffer, pH 6.7.
  • the chromatography separated free PEG from PEG-S- mSOD.
  • the PEG-S-mSOD peak was detected by a UV detector set at 230 nm and the free PEG peak by a refractive index detector.
  • the amount of free PEG in the sample was determined by integrating the area of the peak.
  • a standard curve of peak area versus concentration of PEG was constructed by injecting solutions of PEG-5000 of known concentrations.
  • SOD Activity Assay The enzyme activity of SOD was measured by the method described by McCord and Fridovich (op. cit.) .
  • the initial range of trial pHs was developed based on data from preformulation studies including circular dichro- ism (CD) spectroscopy, differential scanning calorimetry (DSC) , atomic absorption (AA) spectroscopy, and stability tests under various conditions.
  • CD circular dichro- ism
  • DSC differential scanning calorimetry
  • AA atomic absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulation aqueuse d'un conjugé d'une superoxyde de dismutase de mammifère avec un polyéthylène glycol (PEG-SOD) comprenant PEG-SOD et un tampon non-chélateur, dont le pH se situe dans une plage comprise entre 5 à 6,5. L'invention concerne également un procédé d'utilisation de ladite formulation dans la prévention et le traitement de lésions oxydantes chez un mammifère.
EP92917825A 1991-08-05 1992-08-04 Formulation tamponnee de peg-sod Withdrawn EP0598037A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74025591A 1991-08-05 1991-08-05
US740255 1991-08-05
PCT/US1992/006433 WO1993002701A1 (fr) 1991-08-05 1992-08-04 Formulation tamponnee de peg-sod

Publications (1)

Publication Number Publication Date
EP0598037A1 true EP0598037A1 (fr) 1994-05-25

Family

ID=24975708

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92202423A Withdrawn EP0535723A1 (fr) 1991-08-05 1992-08-04 Composition tamponnée de PEG-SOD
EP92917825A Withdrawn EP0598037A1 (fr) 1991-08-05 1992-08-04 Formulation tamponnee de peg-sod

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP92202423A Withdrawn EP0535723A1 (fr) 1991-08-05 1992-08-04 Composition tamponnée de PEG-SOD

Country Status (7)

Country Link
EP (2) EP0535723A1 (fr)
JP (1) JPH06509582A (fr)
AU (1) AU666325B2 (fr)
CA (1) CA2114240A1 (fr)
HU (1) HUT67006A (fr)
MX (1) MX9204545A (fr)
WO (1) WO1993002701A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101361A1 (fr) * 1992-08-27 1994-02-28 Robert A. Snow Substances proteiniques a action biologique liees a un oxyde de polyalkylene a faible teneur en diols
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
JPH0610138B2 (ja) * 1988-07-12 1994-02-09 日本化薬株式会社 スーパーオキシドディスムターゼ組成物
EP0424033A3 (en) * 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9302701A1 *

Also Published As

Publication number Publication date
AU666325B2 (en) 1996-02-08
CA2114240A1 (fr) 1993-02-18
JPH06509582A (ja) 1994-10-27
HU9400328D0 (en) 1994-05-30
AU2430692A (en) 1993-03-02
EP0535723A1 (fr) 1993-04-07
MX9204545A (es) 1993-02-01
HUT67006A (en) 1995-01-30
WO1993002701A1 (fr) 1993-02-18

Similar Documents

Publication Publication Date Title
US5334382A (en) Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US5283317A (en) Intermediates for conjugation of polypeptides with high molecular weight polyalkylene glycols
US5006333A (en) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU675798B2 (en) Low diol polyalkylene oxide biologically active proteinaceous substances
US5438040A (en) Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
EP0875253B1 (fr) Compositionsde chondroitinase
US20030129159A1 (en) Derivatisation of proteins
EP0377613B1 (fr) Conjugues de dismutase de peroxyde
ZA200207206B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates.
JPH01502434A (ja) 新規インシュリン誘導体
Boccu et al. Coupling of monomethoxypolyethyleneglycols to proteins via active esters
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
EP0246569A2 (fr) Dérivés de la superoxyde dismutase, méthode pour les produire et composition pharmaceutique
AU666325B2 (en) Buffered formulation of peg-sod
US4968495A (en) Chemically modified bilirubin oxidase
US20210380962A1 (en) Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
Vincentelli et al. Poly (ethylene glycol) derivatized prodrugs through mixed disulfide bond formation: preliminary report on captopril

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19960301

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19971022